Safety Assessment and Probiotic Potential Comparison of Bifidobacterium longum subsp. infantis BLI-02, Lactobacillus plantarum LPL28, Lactobacillus acidophilus TYCA06, and Lactobacillus paracasei ET-66
-
Published:2023-12-29
Issue:1
Volume:16
Page:126
-
ISSN:2072-6643
-
Container-title:Nutrients
-
language:en
-
Short-container-title:Nutrients
Author:
Chen Jui-Fen1, Hsia Ko-Chiang1, Kuo Yi-Wei2ORCID, Chen Shu-Hui3, Huang Yen-Yu1ORCID, Li Ching-Min1, Hsu Yu-Chieh1ORCID, Tsai Shin-Yu1, Ho Hsieh-Hsun123
Affiliation:
1. Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan 2. Functional Investigation Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan 3. Process Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan
Abstract
Bifidobacterium longum subsp. infantis BLI-02, Lactobacillus paracasei ET-66, Lactobacillus plantarum LPL28, and Lactobacillus acidophilus TYCA06, isolated from healthy breast milk, miso, and the healthy human gut, were assessed for safety in this study. BLI-02, LPL28, TYCA06, and ET-66 exhibited no antibiotic resistance and mutagenic activity in the Ames test at the highest dosage (5000 μg/plate). No genotoxicity was observed in micronucleus and chromosomal aberration assays in rodent spermatogonia at the maximum dosage of 10 g/kg body weight (BW). No acute and sub-chronic toxicity occurred in mice and rats at the maximum tested dosage of 10 g/kg BW and 1.5 g/kg BW, respectively. The lyophilized powder of these strains survived a low pH and high bile salt environment, adhering strongly to Caco-2 cells. Unique antimicrobial activities were noted in these strains, with BLI-02 demonstrating the best growth inhibition against Vibrio parahaemolyticus, LPL28 exhibiting the best growth inhibition against Helicobacter pylori, and ET-66 showing the best growth inhibition against Aggregatibacter actinomycetemcomitans. Based on the present study, the lyophilized powder of these four strains appears to be a safe probiotic supplement at tested dosages. It should be applicable for clinical or healthcare applications.
Funder
Glac Biotech Co., Ltd.
Subject
Food Science,Nutrition and Dietetics
Reference68 articles.
1. Safety of probiotic bacteria;Donohue;Asia Pac. J. Clin. Nutr.,1996 2. On the safety of lactic acid bacteria from food;Adams;Int. J. Food Microbiol.,1995 3. Araya, M., Morelli, L., Reid, G., Sanders, M.E., Stanton, C., Pineiro, M., and Ben Embarek, P. (2002). Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food, Food and Agriculture Organization of the United Nations. 4. Comparative Studies on the Bifidus Flora in the Feces of Infants and Adults. With a Contribution to Classification and Nomenclature of Bifidus Strains;Reuter;Zentralbl. Bakteriol. Orig.,1963 5. Unification of Bifidobacterium infantis and Bifidobacterium suis as Bifidobacterium longum;Sakata;Int. J. Syst. Evol. Microbiol.,2002
|
|